Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Equivalents (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Cash & Equivalents for 16 consecutive years, with $108.7 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 21.06% year-over-year to $108.7 million; the TTM value through Mar 2026 reached $108.7 million, up 21.06%, while the annual FY2025 figure was $120.5 million, 5.62% down from the prior year.
  • Cash & Equivalents hit $108.7 million in Q1 2026 for Corcept Therapeutics, down from $120.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $299.9 million in Q1 2023 and bottomed at $35.3 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $119.0 million, with a median of $120.5 million recorded in 2025.
  • Year-over-year, Cash & Equivalents plummeted 62.96% in 2022 and then skyrocketed 387.68% in 2023.
  • Corcept Therapeutics' Cash & Equivalents stood at $66.3 million in 2022, then surged by 104.36% to $135.6 million in 2023, then fell by 5.82% to $127.7 million in 2024, then dropped by 5.62% to $120.5 million in 2025, then dropped by 9.76% to $108.7 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $108.7 million, $120.5 million, and $125.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.